Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Carl Icahn Can’t Stop Buying Cheniere; Nelson Peltz Boosts Stake In SYSCO

Page 1 of 2

Most individual investors already know the value of monitoring activist investors, who generally make value-enhancing proposals or push for changes at struggling companies in order to unlock shareholder value. Activist hedge funds are the few financial vehicles that do have a strong and consistent track record of beating the broader market even amid the equities bull-run we have experienced over the past several years. Indeed, this is one of the primary reasons the Insider Monkey team tracks and reports the moves made by activists on a daily basis. With this in mind, this article will discuss a bunch of filings submitted by two famous activist investors and one occasional activist monitored by our team.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 102% and beating the market by more than 53 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

In a Form 4 filing with the SEC, Nelson Peltz’s Trian Partners reported purchasing 613,221 shares of SYSCO Corporation (NYSE:SYY) this week at prices in the range of $40.57 to $41.30 per share, boosting Trian’s overall holdings in the company to 42.68 million shares. The well-known activist fund reported owning 41.41 million shares in SYSCO in the latest round of 13Fs. The marketer and distributor of foodservice products delivered modest revenue growth in the first quarter of its fiscal 2016, which was hindered by cost deflation and negative impact of foreign currency translation. Although the U.S. consumer confidence has been on a rise and the labor market has been tightening lately, the foodservice market has been experiencing a modest level of growth, which has resulted in competitive pricing pressures. SYSCO Corporation (NYSE:SYY) reported sales of $13 billion for the first quarter of fiscal 2016, up by 0.9% year-on-year. Its adjusted net earnings climbed 0.9% on the year to $312 million. Meanwhile, shares of SYSCO are up by nearly 4% since the beginning of the year and are trading at a rather expensive trailing price-to-earnings ratio of 37.72, which is significantly above the average of 22.71 for the S&P 500 Index.

A total of 30 funds from our database were invested in SYSCO at the end of the third quarter, amassing 14.90% of the company’s outstanding common stock. These investors owned $3.45 billion worth of shares on September 30. Although the number of smart money investors with positions in the company increased by one quarter-over-quarter, the value of their investments grew by a whopping 56%. Jim Simons’ Renaissance Technologies acquired a 3.49 million-share stake in SYSCO Corporation (NYSE:SYY) during the third quarter.

Nelson Peltz
Nelson Peltz
Trian Partners

Let’s head to the next page of this article, where we discuss two separate filings submitted by Camber Capital Management and Icahn Enterprises.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!